RNAi inhibition of alpha-ENaC expression

Details for Australian Patent Application No. 2012203768 (hide)

Owner Novartis AG

Inventors Van Heeke, Gino; Hickman, Emma; Danahay, Henry Luke; Tan, Pamela; Geick, Anke; Vornlocher, Hans-Peter

Agent Davies Collison Cave

Pub. Number AU-A-2012203768

Parent 2008263876

Filing date 27 June 2012

Wipo publication date 19 July 2012

International Classifications

A61K 31/713 - Double-stranded nucleic acids or oligonucleotides

C07H 21/00 Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

C12N 15/113 Mutation or genetic engineering - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Event Publications

12 July 2012 Complete Application Filed

19 July 2012 Application Open to Public Inspection

  Published as AU-A-2012203768

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2012203780-RNAi inhibition of alpha-ENaC expression

2012203766-Satellite navigation system fault detection based on biased measurements